Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yousaijin injection in acute ischemic stroke
CTR20221839Phase 2Completed
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of meglumine ginkgolide injection in ischemic stroke (4 arms), sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd. Primary endpoints: Adverse events/adverse reactions, Proportion of patients with modified Rankin Scale (mRS) score 0–1 and 8 more. Started Jul 2022; status: completed.
02
Drugs
meglumine ginkgolide injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20221839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221839.